Compound Notes 4 min read
Selank: The Russian Anxiolytic the Supplement Industry Hasn’t Figured Out How to Sell
A sharp look at Selank, why this anxiolytic peptide has stayed niche while less-evidenced compounds got mainstream attention, and what the published research actually supports for buyers cutting through the marketing.
Last reviewed: May 2026
Selank is a synthetic peptide developed at the Russian Academy of Sciences in the 1990s, derived from a fragment of the natural immunopeptide tuftsin. It has been studied in Russia for over two decades, used in clinical practice in some Russian psychiatric settings, and quietly available in the research-peptide category in international markets for almost as long. By any reasonable measure of supplement-industry attention, Selank should be a product everyone has heard of. It is anxiolytic without the sedation of benzodiazepines. It does not produce dependence. It works intranasally, which avoids the injection-fear barrier that limits some compounds.
And yet the supplement industry has not figured out how to sell it. There is a reason for that, and the reason tells you something useful about how peptide marketing actually works.
What Selank actually does, briefly
The compound is a tuftsin analogue with a stabilising glycine-glycine extension. The structural modifications mean Selank survives in plasma longer than tuftsin itself, which would otherwise be cleaved by peptidases within minutes. The mechanism, characterised across multiple Russian and a few Western studies, involves modulation of GABA-A receptor activity (the same receptor system targeted by benzodiazepines and ethanol) along with effects on serotonin and dopamine signalling.
The behavioural profile in animal models is anxiolytic without sedation. Animals show reduced anxiety-related behaviours without the motor impairment that benzodiazepines produce. The human research, mostly Russian, supports a similar pattern: reduced anxiety, mild positive effect on mood, no sedation, no dependence. Standard intranasal doses run 250 to 500 micrograms per spray, several times daily.
Why the supplement industry hasn’t run with it
This is the part worth thinking about. Selank has more clinical evidence than half the nootropics on the consumer market. It has a clean side-effect profile. It has a genuine mechanism. It works.
The supplement industry hasn’t built a category around it because Selank doesn’t fit the supplement-industry sales motion. It is not patented in a way that creates marketing exclusivity. The clinical research is in Russian, which slows the Western literature review and makes citation pages awkward. The compound is research-grade only, which limits the marketing channels. And it competes implicitly with prescription anxiolytics, which is a regulatory minefield no consumer brand wants to walk into.
The result is that Selank has remained quiet in the consumer space while compounds with weaker evidence have become big sellers. This is the supplement industry’s selection bias in action. What gets marketed is not what works best. It is what fits the marketing motion.
What the published research actually supports
The cleanest claims, drawn from the available literature:
- Selank reduces anxiety-related symptoms in adults with generalised anxiety, in placebo-controlled trials with effect sizes that are modest but statistically meaningful.
- The compound does not produce sedation, motor impairment, or measurable dependence on the timescales studied.
- Cognitive effects (memory, attention) appear in some studies as a secondary outcome, with mixed magnitudes. The compound is not primarily a nootropic.
- Intranasal delivery produces the cleanest pharmacokinetics. Other routes have been explored less extensively.
What the research does not support: claims that Selank is a benzodiazepine replacement for clinical anxiety disorders, claims that it produces dramatic cognitive enhancement, or claims that it is a stimulant. The realistic effect is mild-anxiolytic with a clean profile, not a category-bending cognitive compound.
What Selank is for
Researchers who include Selank in a protocol typically do so for one of three reasons:
- Persistent low-grade anxiety that interferes with work or sleep, where the goal is mild attenuation rather than full clinical treatment
- High-stress work periods where a non-sedating anxiolytic profile is the requirement
- Pairing with a cognitive peptide (commonly Semax) where Selank handles the stress regulation and the other compound addresses focus or cognition
The compound is not a substitute for a clinician’s input on actual anxiety disorders. Researchers with diagnosed anxiety conditions should treat Selank as one input among several in a broader plan, not as a primary intervention.
What pairs with Selank
- Semax as the focus side of the cognitive stack, covered in our Semax piece
- Nightfall as the sleep-architecture supplement layer, since chronic anxiety and disrupted sleep tend to compound
The Protocol Builder Cognitive goal includes Selank in the curated stack where stress regulation is the protocol target.
The honest framing
Selank is an unusual case. The evidence is real, the compound is well-tolerated, and the supplement industry has mostly ignored it because the marketing economics do not work. For researchers willing to read the literature directly, Selank is one of the better-positioned compounds in the cognitive-peptide category. The marketing-driven category leaders are not always the evidence-driven category leaders.
The clinical line
Selank is research-grade only, not approved as a medicine, not a licensed supplement, not for human or veterinary application. Personalised clinical questions about anxiety, mood, or cognitive function belong with a UAE-licensed healthcare professional.